Paramune develops novel biologic therapies that modulate the immune system to treat inflammatory diseases and cancer. Their approach focuses on leveraging the body's natural defenses to restore health.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for inflammatory diseases and cancer often fail to address the underlying molecular mechanisms, leading to suboptimal efficacy and potential safety concerns. There remains a need for therapies that can more effectively modulate the immune system to restore health in these patients.
Solution
Paramune is developing biologic therapies that target fundamental molecular mechanisms to more effectively treat cancers and autoimmune diseases. The company engineers therapeutic molecules, such as monoclonal antibodies, bispecifics, engagers, and antibody cocktails, to engage identified targets with high efficacy and improved safety profiles. By focusing on novel targets arising from new discoveries in disease pathology, Paramune aims to achieve superior results compared to existing therapeutic approaches.
Target Audience
The primary target audience includes patients with autoimmune diseases and various forms of cancer, as well as the healthcare providers who treat them.
Features
- Utilizes next-generation biologic formats, including monoclonal antibodies, bispecifics, engagers, and antibody cocktails.
- Rigorously engineered therapeutic molecules designed to engage specific disease targets.
- Focuses on novel molecular mechanisms to treat cancers and autoimmune diseases.
- Aims to deliver greater efficacy with outstanding safety profiles compared to current therapeutic approaches.